Abstract
Background: V591 (TMV-083) is a live recombinant measles vector-based vaccine candidate expressing a pre-fusion stabilized SARS-CoV-2 spike protein.
Methods: We performed a randomized, placebo-controlled Phase I trial with an unblinded dose escalation and a double-blind treatment phase at 2 sites in France and Belgium to evaluate the safety and immunogenicity of V591. Ninety healthy SARS-CoV-2 sero-negative adults (18-55 years of age) were randomized into 3 cohorts, each comprising 24 vaccinees and 6 placebo recipients. Participants received two intramuscular injections of a low dose vaccine (1 × 10 5 median Tissue Culture Infectious Dose [TCID 50 ]), one or two injections of a high dose vaccine (1 × 10 6 TCID 50 ), or placebo with a 28 day interval. Safety was assessed by solicited and unsolicited adverse events. Immunogenicity was measured by SARS-CoV-2 spike protein-binding antibodies, neutralizing antibodies, spike-specific T cell responses, and anti-measles antibodies. ClinicalTrials.gov, NCT04497298 .
Findings: Between Aug 10 and Oct 13, 2020, 148 volunteers were screened of whom 90 were randomized. V591 showed a good safety profile at both dose levels. No serious adverse events were reported. At least one treatment-related adverse event was reported by 15 (20.8%) participants receiving V591 vs. 6 (33.3%) of participants receiving placebo. Eighty-one percent of participants receiving two injections of V591 developed spike-binding antibodies after the second injection. However, neutralizing antibodies were detectable on day 56 only in 17% of participants receiving the low dose and 61% receiving the high dose (2 injections). Spike-specific T cell responses were not detected. Pre-existing anti-measles immunity had a statistically significant impact on the immune response to V591, which was in contrast to previous results with the measles vector-based chikungunya vaccine.
Interpretation: While V591 was generally well tolerated, the immunogenicity was not sufficient to support further development.
Funding: Themis Bioscience GmbH, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA; Coalition for Epidemic Preparedness Innovations (CEPI).
Keywords: COVID-19; SARS-CoV-2; measles vector; vaccine.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, measles vector, 【초록키워드】 neutralizing antibody, antibodies, Vaccine, High dose, immune response, immunogenicity, Trial, Safety, Immunity, Neutralizing antibodies, antibody, Spike protein, adverse events, Randomized, T cell, SARS-CoV-2 spike protein, T cell responses, low dose, adverse event, France, vaccine candidate, age, Placebo, binding antibodies, Belgium, placebo-controlled, T cell response, safety profile, SARS-CoV-2 spike, dose, Innovation, phase, double-blind, Chikungunya, Intramuscular injection, tissue culture, Support, Serious Adverse Events, Serious Adverse Event, CEPI, placebo recipients, cohorts, injection, Injections, participant, Dose escalation, high dose vaccine, low dose vaccine, Coalition, TCID, while, pre-fusion, Volunteer, responses, subsidiary, vaccinee, THEMIS, was measured, performed, evaluate, healthy, reported, detectable, receiving, screened, median, expressing, statistically significant, Bioscience, Inc., spike-specific T cell, treatment phase, 【제목키워드】 Safety, SARS-CoV-2 vaccine, Randomized, placebo-controlled, phase, healthy,